A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is a single-dose, double-blind, placebo-controlled, parallel group safety, tolerability
and pharmacodynamic study of subcutaneously (SC) administered REGN88 in rheumatoid arthritis
patients who are receiving concomitant methotrexate. Four (4) parallel groups of 8 subjects
each with active rheumatoid arthritis will be dosed SC.